Overview

A Study to Evaluate FK778 in Kidney Transplant Patients

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
A dose finding study to evaluate the safety and effectiveness of FK778 in kidney transplant patients
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Astellas Pharma Europe B.V.